Request Demo
Last update 30 Mar 2025
VIS171
Last update 30 Mar 2025
Overview
Basic Info
Drug Type Interleukins |
Synonyms VIS171 |
Target |
Action modulators, stimulants |
Mechanism IL-2 replacements(Interleukin-2 replacements), IL-2R modulators(Interleukin-2 receptor modulators), Regulatory T-lymphocytes stimulants |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePhase 1 |
First Approval Date- |
Regulation- |
Login to view timeline
Related
3
Clinical Trials associated with VIS171NCT06799520
A Phase 1 Open-label Trial to Evaluate the Safety, Tolerability, Pharmacodynamics, Pharmacokinetics, and Immunogenicity of Subcutaneous VIS171 in Participants With Autoimmune Disease(s)
NCT05418101
A Phase 1, First-in-human, 2-part Study (part 1 is a Single Ascending Dose in Healthy Participants; Part 2 is a Multiple Ascending Dose Study in Participants with Autoimmune Disease) to Evaluate the Safety, PD and PK of VIS171
NL-OMON51485
A phase 1, first-in-human, 2-part, randomized, double-blind, placebo controlled, single ascending dose and sequential, open-label, multiple ascending dose study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and participants with autoimmune disease(s) - VIS171
100 Clinical Results associated with VIS171
Login to view more data
100 Translational Medicine associated with VIS171
Login to view more data
100 Patents (Medical) associated with VIS171
Login to view more data
100 Deals associated with VIS171
Login to view more data
R&D Status
10 top R&D records. to view more data
Login
| Indication | Highest Phase | Country/Location | Organization | Date |
|---|---|---|---|---|
| Alopecia Areata | Phase 1 | United States | 17 Mar 2025 | |
| Systemic Lupus Erythematosus | Phase 1 | United States | 17 Mar 2025 | |
| Autoimmune Diseases | Phase 1 | United States | 28 Apr 2022 | |
| Autoimmune Diseases | Phase 1 | Bulgaria | 28 Apr 2022 | |
| Autoimmune Diseases | Phase 1 | Germany | 28 Apr 2022 | |
| Autoimmune Diseases | Phase 1 | Netherlands | 28 Apr 2022 | |
| Autoimmune Diseases | Phase 1 | New Zealand | 28 Apr 2022 |
Login to view more data
Clinical Result
Clinical Result
Indication
Phase
Evaluation
View All Results
Login to view more data
Translational Medicine
Boost your research with our translational medicine data.
login
or
Deal
Boost your decision using our deal data.
login
or
Core Patent
Boost your research with our Core Patent data.
login
or
Clinical Trial
Identify the latest clinical trials across global registries.
login
or
Approval
Accelerate your research with the latest regulatory approval information.
login
or
Biosimilar
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
login
or
Regulation
Understand key drug designations in just a few clicks with Synapse.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free